NASDAQ:TVGN Tevogen (TVGN) Stock Price, News & Analysis $6.14 +0.45 (+7.91%) Closing price 04:00 PM EasternExtended Trading$6.03 -0.11 (-1.79%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Tevogen Stock (NASDAQ:TVGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tevogen alerts:Sign Up Key Stats Today's Range$5.80▼$6.1950-Day Range$5.11▼$7.8552-Week Range$3.64▼$24.91Volume5,185 shsAverage Volume20,185 shsMarket Capitalization$421.69 millionP/E RatioN/ADividend YieldN/APrice Target$100.00Consensus RatingReduce Company Overview Tevogen Inc. is a biotechnology company developing off-the-shelf T-cell therapies. Its approach uses naturally occurring, unmodified immune cells selected to recognize specific targets, with the goal of treating diseases while limiting the need for individualized cell manufacturing. The company’s programs have focused on infectious diseases and cancer. Its investigational candidate TVGN 489 has been developed for potential use against COVID-19, including in people at elevated risk of severe illness. The company also describes broader applications for its T-cell platform in oncology. Founded by physician and biotechnology executive Ryan Saadi, Tevogen is based in the United States. Saadi serves as the company’s chief executive officer. AI Generated. May Contain Errors. Read More Tevogen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreTVGN MarketRank™: 1.909885675855 of 5 starsTevogen scored higher than 38% of companies evaluated by MarketBeat, and ranked 1379th out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingReduce Consensus RatingTevogen has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTevogen has a consensus price target of $100.00, representing about 1,528.7% upside from its current price of $6.14.Amount of Analyst CoverageTevogen has only been the subject of 1 research reports in the past 90 days.Read more about Tevogen's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Tevogen is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tevogen is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.45% of the float of Tevogen has been sold short.Short Interest Ratio / Days to CoverTevogen has a short interest ratio ("days to cover") of 4.33.Change versus previous monthShort interest in Tevogen has recently decreased by 1.02%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTevogen does not currently pay a dividend.Dividend GrowthTevogen does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment1.00 News SentimentTevogen has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Tevogen this week, compared to 2 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tevogen insiders have not sold or bought any company stock.Percentage Held by Insiders65.60% of the stock of Tevogen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsTevogen has minimal institutional ownership at this time.Read more about Tevogen's insider trading history. Receive TVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tevogen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVGN Stock News HeadlinesTevogen Highlights Significant Liability Reduction and Continued Insider Control4 hours ago | globenewswire.comTevogen Complements Capital Access with Two-Year Extension to Loan AgreementNovember 9, 2026 | globenewswire.comBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.November 18 at 1:00 AM | Banyan Hill Publishing (Ad)Tevogen Regains Compliance with Nasdaq Global Market Continued Listing RequirementsSeptember 30, 2026 | globenewswire.comTevogen Bio Holdings Rebrands as Tevogen Inc.July 30, 2026 | tipranks.comTevogen Bio Holdings Corporate Event Calendar | NASDAQ:TVGNJuly 24, 2026 | benzinga.comTevogen Bio Announces 2026 Annual Meeting of StockholdersJuly 13, 2026 | globenewswire.comTevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services InitiativeJune 10, 2026 | finanznachrichten.deSee More Headlines TVGN Stock Analysis - Frequently Asked Questions How have TVGN shares performed this year? Tevogen's stock was trading at $16.5550 on January 1st, 2026. Since then, TVGN shares have decreased by 62.9% and is now trading at $6.14. How were Tevogen's earnings last quarter? Tevogen Inc. (NASDAQ:TVGN) posted its quarterly earnings data on Monday, November, 16th. The company reported ($1.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.56) by $0.80. When did Tevogen's stock split? Shares of Tevogen reverse split before market open on Friday, March 6th 2026.The 1-50 reverse split was announced on Wednesday, March 4th 2026. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 5th 2026. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Tevogen? Shares of TVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tevogen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tevogen investors own include Jaguar Animal Health (JAGX), Micron Technology (MU), NVIDIA (NVDA), D-Wave Quantum (QBTS), Super Micro Computer (SMCI), Tesla (TSLA) and Archer Aviation (ACHR). Company Calendar Last Earnings11/16/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TVGN's financial health is in the Green zone, according to TradeSmith. TVGN has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TVGN Previous SymbolNASDAQ:TVGN CIK1860871 Webwww.tevogen.com Phone(646) 807-8832FaxN/AEmployees18Year FoundedN/APrice Target and Rating Average Price Target for Tevogen$100.00 High Price Target$100.00 Low Price Target$100.00 Potential Upside/Downside+1,528.7%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($4.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.27 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-495.15% Debt Debt-to-Equity RatioN/A Current Ratio0.33 Quick Ratio0.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($211.84) per share Price / Book-0.03Miscellaneous Outstanding Shares68,678,743Free Float2,240,000Market Cap$421.69 million OptionableN/A Beta0.21 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:TVGN) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.